These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 23777549)

  • 1. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study).
    Young EJ; Tabrizi SN; Brotherton JM; Wark JD; Pyman J; Saville M; Wrede CD; Jayasinghe Y; Tan J; Gertig DM; Pitts M; Garland SM
    BMC Cancer; 2013 Jun; 13():296. PubMed ID: 23777549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
    BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HPV16/18 prevalence in high-grade cervical lesions in an Australian population offered catch-up HPV vaccination.
    Cornall AM; Saville M; Pyman J; Callegari ET; Tan FH; Brotherton JML; Malloy MJ; Tabrizi SN; Wrede CD; Garland SM;
    Vaccine; 2020 Sep; 38(40):6304-6311. PubMed ID: 32736938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program.
    Osborne SL; Tabrizi SN; Brotherton JM; Cornall AM; Wark JD; Wrede CD; Jayasinghe Y; Gertig DM; Pitts MK; Garland SM;
    Vaccine; 2015 Jan; 33(1):201-8. PubMed ID: 25444787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
    Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
    Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
    Mahmud SM; Kliewer EV; Lambert P; Bozat-Emre S; Demers AA
    J Clin Oncol; 2014 Feb; 32(5):438-43. PubMed ID: 24395857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
    Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
    Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
    Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
    Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colposcopic performance in a birth cohort previously eligible for human papillomavirus vaccination.
    Sahlgren HAI; Elfgren K; Sparen P; Elfstrom MK
    Am J Obstet Gynecol; 2022 May; 226(5):704.e1-704.e9. PubMed ID: 34954217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.
    FUTURE II Study Group
    J Infect Dis; 2007 Nov; 196(10):1438-46. PubMed ID: 18008221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
    Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
    J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
    Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
    Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.
    Shiko Y; Konno R; Konishi H; Sauvaget C; Ohashi Y; Kakizoe T
    BMC Infect Dis; 2020 Nov; 20(1):808. PubMed ID: 33153446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.
    Joura EA; Ault KA; Bosch FX; Brown D; Cuzick J; Ferris D; Garland SM; Giuliano AR; Hernandez-Avila M; Huh W; Iversen OE; Kjaer SK; Luna J; Miller D; Monsonego J; Munoz N; Myers E; Paavonen J; Pitisuttithum P; Steben M; Wheeler CM; Perez G; Saah A; Luxembourg A; Sings HL; Velicer C
    Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1997-2008. PubMed ID: 25274978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.